Moteur de recherche d’entreprises européennes
Financement de l’UE (8 784 039 €) : Accélérer la transition du laboratoire vers le marché des outils d’IA pour la prise en charge du cancer Hor12/06/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Accélérer la transition du laboratoire vers le marché des outils d’IA pour la prise en charge du cancer
CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. An EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries. It will build on partner´s experience (e.g. PRIMAGE repository for paediatric cancer and the Euro-BioImaging node for Valencia population, by HULAFE; the Radiomics Imaging Archive by Maastricht University; the national repository DRIM AI France, the Oncology imaging biobank by Pisa University). Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed lung, prostate, colon and rectal cancer patients. A multimodal analytical data engine will facilitate to interpret, extract and exploit the right information stored at the Repository. An ambitious development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and images harmonisation, the latest being of the highest importance for enabling reproducibility of Radiomics when using large multiscanner/multicentre image datasets. The usability and performance of the Repository as a tool fostering AI experimentation will be validated, including a validation subphase by other world-class European AI developers, articulated via the organisation of Open Challenges to the AI Community. A set of selected AI tools will undergo early on-silico validation in observational (non-interventional) clinical studies coordinated by leading experts in Gustave Roussy (lung cancer), San Donato (breast), Sapienza (colon and rectal) and La Fe (prostate) hospitals. Their performance will be assessed, including external independent validation, on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer.
| Bahia Software SL | 512 188 € |
| BC Platforms | 677 500 € |
| BEN-Gurion University OF THE Negev | 466 250 € |
| Charite - Universitaetsmedizin Berlin | 531 875 € |
| College des Enseignants de Radiologie de France | 413 750 € |
| Eibir Gemeinnutzige GmbH ZUR Forderung DER Erforschung DER Biomedizinischen Bildgebung | 263 750 € |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | 1 113 125 € |
| GE Healthcare GmbH | 567 685 € |
| Imperial College of Science Technology and Medicine | 508 951 € |
| Matical Innovation SL | 286 000 € |
| Policlinico SAN Donato S.p.A. | 386 875 € |
| Quibim SL | 458 750 € |
| Unidade Local de Saude de Santo Antonio ΕΠΕ | 198 340 € |
| Universita Degli Studi Di Roma LA Sapienza | 463 125 € |
| Universita Di Pisa | 357 500 € |
| Universitat de Valencia | 341 875 € |
| Universitat Politecnica de Valencia | 658 188 € |
| Universiteit Maastricht | 578 313 € |
https://cordis.europa.eu/project/id/952172
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.